Chinese herbal medicine to prevent liver cancer in hepatitis B patients
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests whether Babao Dan, a traditional Chinese medicine capsule, combined with antiviral drugs can reduce the risk of liver cancer in people with hepatitis B-related cirrhosis (advanced liver scarring). The study aims to see if this combination helps protect your liver and prevent cancer development.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been diagnosed with hepatitis B-related cirrhosis (your liver is scarred from chronic hepatitis B)
- Your liver function meets specific criteria (aMAP score greater than 60)
- You have the TCM syndrome type called Shi-re-du-yun (a traditional Chinese medicine diagnosis pattern)
- You have never been diagnosed with or treated for liver cancer or other cancers
- Your cirrhosis is not severely advanced (no major fluid buildup in belly, confusion, or bleeding from stomach)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a traditional Chinese medicine called Fufang Biejiaruangan, taken with standard antiviral drugs, can lower the risk of liver cancer in people with hepatitis B-related cirrhosis. Participants will be randomly assigned to receive the medicine or a placebo to see if it helps prevent liver cancer.
This trial tests a Chinese herbal compound to see if it helps people with liver cancer stay cancer-free longer after surgery or ablation. It is for patients with hepatitis B-related liver damage who have had their tumor completely removed.
This trial tests whether continuing antiviral therapy after surgery for hepatitis B-related liver cancer can improve outcomes. It focuses on patients with early-stage disease, good liver function, and no prior cancer treatments other than surgery or ablation.
This early-stage trial tests whether a drug called pegylated interferon alpha-2β can help prevent hepatitis B-related liver cancer from coming back after surgery. The drug aims to boost your immune system to fight any remaining cancer cells.
This trial tests whether taking vitamin D by mouth can lower the risk of developing liver cancer (hepatocellular carcinoma) in adults with long-term hepatitis B. It may help by supporting liver health over time, especially for people already on hepatitis B antiviral treatment.
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.